Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

Core Insights - Halozyme Therapeutics (HALO) is positioned to continue its earnings-beat streak, particularly in the upcoming report, with a history of surpassing earnings estimates [1][2] - The company has achieved an average surprise of 21.02% over the last two quarters, indicating strong performance [1] Earnings Performance - For the most recent quarter, Halozyme reported earnings of $1.54 per share, exceeding the expected $1.23 per share by 25.20% [2] - In the previous quarter, the company reported $1.11 per share against an expectation of $0.95 per share, resulting in a surprise of 16.84% [2] Earnings Estimates and Predictions - Recent estimates for Halozyme have been increasing, with a positive Earnings ESP (Expected Surprise Prediction) indicating a likelihood of another earnings beat [5][8] - The current Earnings ESP for Halozyme is +1.48%, suggesting analysts are optimistic about the company's earnings prospects [8] Zacks Rank and Predictive Power - Halozyme holds a Zacks Rank of 2 (Buy), which, when combined with a positive Earnings ESP, suggests a high probability of beating earnings estimates [8] - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]